31 / 36
GENETIC ALTERATIONS IN THE MAPK PATHWAY
WERE NOT ASSOCIATED WITH CLINICAL
OUTCOME/RESPONSE TO THERAPY
PRESENTED BY GV LONG AT ESMO 2018
amp, amplification; BRAFi, BRAF inhibitor; MEKi, MEK inhibitor; mut, mutation.
BRAF
Amplification
MAP2K1
(MEK1) Mutation
RFS, %
RFS, %
0
0
20
40
60
80
100
10 20 30 40 50 60
168 94 74 67 51 18 1
14 8 4 4 3
12 12 9 8 6 1
174 155 109 87 62 19
0
0
20
40
60
80
100
10 20 30 40 50 60
172 97 75 69 53 17 1
10 5 3 2 1
10 9 7 6 5 1
1
176 158 111 89 63 19
Months
Months
D+T, no amplification
D+T, amplification
PBO, no amplification
PBO,
amplification
D+T, no amp
D+T, amp
PBO, no amp
PBO, amp
D+T, no mutation
D+T, mutation
PBO, no mutation
PBO, mutation
D+T, no mut
D+T, mut
PBO, no mut
PBO, mut
0 0
0
0
0
0
0
No. at risk
No. at risk
Mutations in MAPK Pathway
RFS, %
0
0
20
40
60
80
100
10 20 30 40 50 60
153 86 68 62 48 17 1
29 16 10 9 6
40 37 24 20 17 3
1
146 130 94 75 51 17
Months
D+T, no mutation
D+T, mutation
PBO, no mutation
PBO, mutation
D+T, no mut
D+T, mut
PBO, no mut
PBO, mut
0
0
0
No. at risk